Radiopharm Theranostics announced a US$4.1 million registered direct offering of American Depositary Shares to U.S. investors, alongside unregistered warrants exercisable after shareholder approval. Concurrently, the company secured commitments for an Australian private placement worth approximately A$6.7 million and plans a Share Purchase Plan to raise up to an additional A$6 million, both subject to shareholder approval. The funds will support clinical trials, strategic partnerships, and general corporate purposes. The company expects to hold a shareholder meeting by September 11, 2026, to approve the offerings and related options issuance.
Investec Bank plc, acting as advisor and joint broker to Advanced Medical Solutions Group Plc, disclosed its share transactions on July 23, 2026. The bank purchased 640,099 ordinary shares at prices between 280 and 280.25 per unit and sold 650,000 sh...
Novo Resources Corp's initial reverse circulation drilling at its Wyloo Polymetallic Project in Western Australia uncovered a significant hydrothermal alteration system with high-grade silver and antimony mineralisation from surface. This discovery i...
TelyRx Holdings Inc., a healthcare and pharmacy services company, announced it will release its second quarter 2026 financial results on August 10, 2026, at 7:00 a.m. Eastern Time. The company will host a conference call and live webcast at 8:30 a.m....
Bitcoin options on Deribit show a $5 billion open interest concentrated at the $70,000 and $72,000 call strikes, reflecting strong bullish sentiment. Calls outnumber puts by a large margin, driven by large bull call spreads and outright call purchase...
AppLovin's stock has fallen nearly 17%, presenting a strong buying opportunity according to analyst Oliver Rodzianko. The company expects 53% revenue growth and 60% adjusted EBITDA growth year-over-year, driven by digital advertising and its AXON and...
